Inhibition of choroidal neovascularization by topical application of angiogenesis inhibitor vasostatin by Sheu, Shwu-Jiuan et al.
Inhibition of choroidal neovascularization by topical application of
angiogenesis inhibitor vasostatin
Shwu-Jiuan Sheu,1,2 Youn-Shen Bee,1,3 Yi-Ling Ma,3 Guei-Sheung Liu,4 Hsiu-Chen Lin,1 Tse-Liang Yeh,5
Jau-Chen Liou,3 Ming-Hong Tai3,4,6
(The first two authors contributed equally to this work.)
1Department of Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; 2School of Medicine, National Yang-
Ming University, Taipei, Taiwan; 3Department of Biological Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan;
4Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; 5Department of
Mechanical Engineering, National Central University, Chung-Li, Taiwan; 6Institute of Biomedical Sciences, National Sun Yat-Sen
University, Kaohsiung, Taiwan
Purpose: Choroidal neovascularization (CNV) is the leading cause of blindness in patients with age-related macular
degeneration (AMD). This study evaluated the inhibitory effect of vasostatin (VS), an endogenous angiogenesis inhibitor,
on CNV.
Methods: Anti-angiogenic activity of VS was evaluated in vitro by migration and tube formation assays in human
umbilical vein endothelial cells (HUVECs). CNV lesions were induced in Brown Norway rats by fundus argon laser
photocoagulation. Beginning one day after CNV induction, rats were treated with eye drops containing 1 μg/ml VS in
PBS buffer for three times daily for 20 days. The extent of CNV was examined by flat mount analysis on day 24 or by
fundus fluorescein angiography (FAG) on days 21, 28, 35, and 42, respectively. CNV lesions and choroidal vascularity
were evaluated by histological analysis. The spatial distribution of topically applied VS in rat eyes was evaluated by
immunoblot analysis.
Results: VS inhibited migration and tube formation in HUVECs. Flat mount analysis revealed that, after laser-induced
photocoagulation, topical VS application for 20 days significantly reduced CNV lesions. Moreover, serial FAG analysis
indicated that a 20 day VS treatment significantly reduced CNV lesions on all subsequent days. Histological analysis
revealed attenuated lesions, intact Bruch’s membrane, and reduced choroidal vascularity in VS-treated eyes. Finally
immunoblot analysis reveled VS expression in choroids.
Conclusions: Topical VS application suppresses the progression of laser-induced CNV via angiogenesis inhibition and
may constitute a therapeutic alternative for excessive neovascularization occurring with ocular diseases.
Choroidal neovascularization (CNV) is the primary cause
for  vision  loss  in  patients  with  age-related  macular
degeneration (AMD) [1]. In patients with the exudative or
“wet”  form  of  the  disease,  choroidal  blood  vessels  grow
through Bruch’s membrane into the subretinal space, followed
by leakage and accumulation of serum or blood beneath the
retinal pigment epithelium (RPE), leading to retinal insult and
rapid vision loss [2]. CNV is frequently observed in patients
with high myopia, angioid streaks, inflammation, or diabetic
retinopathy. Although the molecular basis for CNV is not well
understood, an imbalance between pro-angiogenic and anti-
angiogenic  factors  has  been  proposed  in  pathologic
neovascularization [1,3]. Vascular endothelial growth factor
(VEGF) has been identified as a validated target for several
retinal vascular diseases, including CNV [4-12]. In turn, this
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led to the development of VEGF-neutralizing oligonucleotide
aptamer (pegaptanib) [4], humanized anti-VEGF monoclonal
antibody bevacizumab (Avastin) [5-8], and humanized anti-
VEGF monoclonal antibody fragment (ranibizumab) [9-12]
for  CNV  treatment.  In  particular,  ranibizumab  and
bevacizumab have shown promise in treating CNV and AMD
[3-8]. However, these modalities require repeated intravitreal
injections,  which  can  result  in  endophthalmitis  or  retinal
detachment. Thus, effective anti-angiogenesis therapies that
could be continuously administrated through a noninvasive
route are in demand for long-term control of CNV.
Vasostatin (VS), the N-terminal domain (amino acids 1–
180) of calreticulin, is a potent angiogenesis inhibitor isolated
from  culture  supernatants  of  an  Epstein-Barr  virus-
immortalized cell line [13-15]. Recombinant VS has been
shown  to  inhibit  basic  fibroblast  growth  factor  (bFGF)-
induced or VEGF-induced endothelial cell proliferation in
vitro  [13,16].  Administration  of  recombinant  VS  protein
reduced  growth  of  human  Burkitt  lymphoma  and  colon
carcinoma in murine models [14,15]. In our previous studies,
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1897intramuscular VS gene delivery led to elevated VS levels in
circulation, profoundly inhibiting tumor growth and CNV in
animals [17,18]. Since eye drops are commonly used for long-
term treatment of ocular diseases, we evaluated the feasibility
of VS for topical application to eyes [16]. VS was found to be
stable in an eye drop solution at 4 °C for at least seven days.
Moreover, topical VS application eliminated bFGF-induced
cornea angiogenesis in rat eyes [16]. Thus, we set out to
investigate whether topically applied VS could exert its anti-
angiogenic function in internal ocular tissues, such as retina,
thereby alleviating CNV induced by laser photocoagulation
in rat eyes.
METHODS
Cell  cultures:  Human  umbilical  vein  endothelial  cells
(HUVECs; passage 3 to 6; Sigma Chemical Co; St. Louis,
MO)  were  isolated  from  umbilical  veins  as  previously
described  [19]  and  cultured  in  Medium  199  (Life
Technologies, Gaithersburg, MD) containing 15% fetal calf
serum, 20 U/ml porcine heparin (Sigma Chemical Co) and
100 µg/ml endothelial cell growth supplement (Calbiochem-
Novabiochem Corp., La Jolla, CA).
Cell  migration  assay:  Migration  assay  was  performed  as
previously described [19]. HUVECs were seeded in triplicate
in the upper compartment of the chamber (1.2×105 cells in
400 μl) and the lower compartment filled with 200 μl of
Dulbecco’s  Modified  Eagle  medium  (DMEM;  Life
Technologies,  Gaithersburg,  MD)  containing  100  ng/ml
bFGF  (R&D  Systems,  Inc.,  Minneapolis,  MN)  as  the
chemoattractant. A polycarbonate filter of 8 μm pore size
(Nucleopore, Costar, Cambridge, MA), coated with 0.005%
gelatin to allow cell adhesion, separated the compartments.
After incubation for 2–4 h in a humidified 5% CO2 atmosphere
at 37 °C, cells on the upper side of the filter were removed.
Those  that  had  migrated  to  the  lower  side  were  fixed  in
absolute methanol, stained with 10% Giemsa solution (Merck
KGaA,  Darmstadt,  Germany),  and  counted  as  a  mean
±standard error of the mean (SEM) per filter under five high
power fields from an microscope (Olympus BX40; Olympus
Optical Co., Tokyo, Japan; 50×, 100×, 200×, 300×, and 400×
magnification).
Tube formation assay: Tube formation assay was performed
as  previously  described  [19].  Briefly,  Matrigel  (Becton
Dickinson, Bedford, MA) was diluted with 4 °C serum-free
DMEM to 10 mg/ml. The diluted solution was added to a 24
well plate (200 µl per well) and allowed to form a gel at 37 °C
for 30 min. After infection for 24 h, HUVEC (1.5×105 cells
per ml) were incubated with Matrigel, then added to each well
to  incubate  for  6–8  h  at  37  °C  in  5%  CO2.  Under  these
conditions, endothelial cells form delicate networks of tubes
that are detectable within 2–3 h and fully developed after 8–
12 h. After incubation, the endothelial tubes were fixed with
3% paraformaldehyde and counted in three to four different
lower power fields (25×, 40×, 50×, and 100× magnification).
The tube ring was examined daily on an microscope (Olympus
CKX41;  Olympus  Optical  Co.,  Tokyo,  Japan;  400×
magnification) and recorded.
Animals: Brown Norway pigmented rats (weight 200–250 g,
National  Animal  Center,  Taipei,  Taiwan)  were  used.  The
animals  were  handled  in  accordance  with  the  ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research.  Rats  were  anesthetized  with  an  intramuscular
injection of 0.15 ml/kg of an equal-volume mixture of 2%
lidocaine (Xylocaine; Astra, Astra Södertälje, Sweden) and
50 mg/ml ketamine (Ketalar; Parke-Davis, Morris Plains, NJ).
Generation of CNV by laser photocoagulation: CNV lesions
were  induced  in  rat  eyes  by  laser  photocoagulation  as
previously  described  [17,20].  Briefly,  after  the  rats  were
anesthetized, their pupils were dilated with 1% tropicamide
(1% Mydriacyl; Alcon Laboratories, Fort Worth, TX). A piece
of 18x24 mm standard cover glass (Matsunami Glass, Japan)
served as a contact lens. Argon laser (Novus Omni, Coherent,
Inc., Palo Alto, CA) irradiation was delivered through a slit
lamp (Carl Zeiss, Oberkochen, Germany). Laser parameters
were set as follows: spot size of 50 µm, power of 400 mW,
and exposure duration of 0.05 s. An attempt was made to break
Bruch’s membrane, as clinically evidenced by central bubble
formation,  with  or  without  intraretinal  or  choroidal
hemorrhage. Eight lesions were created between the major
retinal vessels in each fundus.
Application of VS eye drops: Recombinant VS was purified
and applied to eyes as previously described [16]. VS eye drops
(1  μg/ml  in  PBS)  were  formulated  in  1  μg/ml  phosphate
buffered saline (PBS; Invitrogen, Gland Island, NY; 10 mM
phosphate buffer, pH 7.4, 150 mM NaCl) and stored at 4 °C.
As with methylcellulose solution, VS is stable in PBS without
significant loss of integrity or anti-angiogenesis for at least
seven days (data not shown). One day after CNV induction,
rats were divided into three groups: untreated (n=8); treated
three times daily with 50 μl VS eye drops (1 μg/ml in PBS;
n=8); or treated three times a day with 50 μl PBS vehicle
(n=8). This was continued for 20 days.
Quantification of CNV by fluorescein isothiocyanate-dextran
labeling:  The  blood  vessels  in  rat  eyes  were  labeled  by
perfusion  with  fluorescein  isothiocyanate  (FITC)-dextran
(2×106 MW; Sigma) as previously described [21,22]. Briefly,
after the animal were euthanized by intramuscular injection
0.3  ml/kg  of  an  equal-volume  mixture  of  2%  lidocaine
(Xylocaine; Astra) and 50 mg/ml ketamine (Ketalar; Parke-
Davis, Morris Plains) on day 24, approximately. The eyes
were removed, then fixed for 2 h in 10% phosphate-buffered
formalin.  After  the  cornea  and  lens  were  removed,  RPE-
choroid-sclera flat mounts were obtained by hemisecting the
eye and peeling the neural retina away from the underlying
RPE. The retina was detached and flat mounted onto a slide.
The  fluorescence  in  flat  mounts  was  examined  by
fluorescence  microscopy  (Olympus  BX40),  and  images
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1898Figure 1. Anti-angiogenic function of
VS in endothelial cells. A: Effect of VS
on  migration  of  HUVECs.  VS  was
added in varying doses, and endothelial
cells were placed in a Boyden chamber
for 6 h and allowed to migrate toward
bFGF.  Shown  are  representative
photographs of endothelial migration in
control and after treatment with 1 μg/ml
VS (left). Cell migration was quantified
by counting cells from three high power
fields and expressed as mean ± SD of
triplicates (right). B: Effect of VS on
tube formation of HUVECs. Endothelial
cells  were  applied  to  Matrigel  and
incubated for 4 h in the presence of VS
of  varying  doses.  Representative
profiles  of  the  tubular  structures  in
control and 1 μg/ml VS-treated HUVEC
are shown (left). Tube formation was
quantified by counting the number of
rings and expressed as mean±SD from
quadruplicates  (right).  Asterisk  (*)
represents p<0.05, and double asterisk
(**) represents p<0.01.
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1899digitized using a three-color charge coupled video camera and
frame  grabber  (Olympus  DP70).  The  area  of
hyperfluorescence  associated  with  each  burn  –  the  CNV
lesion – was measured by image analysis software (Image J,
National Institutes of Health, Bethesda, MD).
Assessment  of  choroidal  neovascularization  by  fundus
fluorescein  angiography:  CNV  lesions  were  evaluated  by
fundus fluorescein angiography (FAG) analysis as previously
described  [17].  On  days  21,  28,  35,  and  42  after  laser
photocoagulation,  the  CNV  lesions  were  studied  by  FAG
using a digital fundus camera (Visupac 450, Ziess FF450, Carl
Zeiss,  Oberkochen,  Germany).  Next,  0.1  ml/kg  of  10%
fluorescein sodium solution (Fluorescite, Alcon Laboratories,
Fort Worth, TX) was injected into the intraperitoneal cavity
of anesthetized rats. Late-phase angiograms were obtained 8
min after injection, and digital fundus pictures of bilateral eyes
were taken within 1 min. CNV was defined as presence of
early hyperfluorescence with late leakage at the site of laser
injury.  Incidence  of  CNV  was  calculated  by  dividing  the
number of leaking spots by the number of total laser spots. In
addition, the mean area of CNV was measured using image
analysis software (Retina Angiography Area Measurement,
Heidelberg  Engineering,  Heidelberg,  Germany)  by  two
independent  ophthalmologists  blinded  to  the  experimental
design.
Histological analysis: After the final round of FAG analysis
on day 42, the eyes were enucleated (n=8 rats per group), fixed
for 30 min in 4% paraformaldehyde, embedded in OCT (OCT;
Sakura, Tokyo, Japan), and sectioned to 10 µm thickness. The
frozen sections were stained with hematoxylin and eosin for
examination  under  light  microscope  (Olympus  BX40)  or
immunofluorescence  analysis  using  1:50  dilution  Von
Willebrand  factor  (vWF)  antibodies  (anti-vWF,  Dako
Denmark A/S, Glostrup, Denmark) followed by incubation
with  FITC-conjugated  secondary  antibodies.
Immunofluorescence  analysis  was  performed  under
fluorescent microscopy.
Western blot analysis of VS distribution in ocular tissue: The
distribution of topically applied VS in rat eyes was evaluated
by  western  blot  analysis.  Brown  Norway  rats  (n=4)  were
treated with VS eye drops (1 μg/ml in PBS; 50 µl; 1 µg/ml)
in the right eye and PBS in the left eye three times daily for
14 days. Twelve hours after the final topical application, the
animals  were  euthanized.  The  eyes  were  enucleated  and
dissected  to  collect  the  cornea  and  retinochoroid  tissues.
Subsequently, the ocular tissues were homogenized with lysis
buffer containing 50 mM HEPES, 150 mM NaCl, 1% Triton
X-100, 10% glycerol, 1.5 mM MgCl2, 1 mM EGTA, 1 mM
PMSF,  10  μg/ml  aprotinin,  2  μg/ml  leupetin,  10  μg/ml
pepstatin, 100 mM NaF, 1 mM NaVO4, and 10 mM sodium
pyrophosphate. This material was then centrifuged at 15,300
xg  at  4  °C  for  20  min  to  collect  the  supernatants.
Concentrations of protein supernatants were determined using
Coomassie Plus Protein Assay reagent (Pierce Biotechnology,
Inc.,  Rockford,  IL).  Next,  20  μg  protein  samples  were
separated on 10% SDS–PAGE and transferred onto PVDF
membranes  (Immobilon-P  membrane;  Millipore  Corp.,
Billerica, MA) for subsequent blotting. The recombinant VS
Figure 2. The experimental scheme of
topical VS application for laser-induced
CNV.  A:  Therapeutic  efficacy  was
assessed by flat mount analysis. CNV
was induced by laser photocoagulation
on day 0 and validated on day 21 by
FAG analysis. The animals (n=8) were
euthanized on day 24 to measure CNV
extent by flat mount analysis. B: In serial
FAG  analysis,  CNV  was  induced  by
laser photocoagulation at day 0. From
day 1 to 20 after induction, the animals
were either left untreated (CNV control
group, n=8) or treated with VS eye drops
(1 μg/ml in PBS; CNV+VS group, n=8),
or PBS vehicle (CNV+PBS group; n=8)
three times per day.
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1900protein was detected by applying 1:1,000 dilution anti-6×His
and the samples were allowed to sit overnight at 4 °C. Protein
loading was normalized with 1:10,000 dilution anti-β-actin
antibody (Sigma-Aldrich Co., St. Louis, MO).
Statistical analysis: All data are presented as mean±standard
deviation of indicated repeats. Differences between groups
were analyzed by ANOVA with two-tailed probability. A p
value of less than 0.05 was considered significant. Results
were representative of at least three independent experiments.
All statistical analyses were conducted using SPSS software,
version 15.0.1 (SPSS, Inc., Chicago, IL).
RESULTS
VS inhibited the migration and tube formation of endothelial
cells: Application of VS potently inhibited the migration of
endothelial cells in a dose-dependent manner (Figure 1A). In
addition,  application  of  various  doses  of  VS  significantly
reduced the capability of endothelial cells to form tube-like
structures in Matrigel (Figure 1B). Together, these results
indicate that VS perturbed the motility and tube formation of
endothelial cells.
Topical application of VS alleviated the laser-induced CNV
lesions:  The  present  study  employed  the  model  of  laser-
induced photocoagulation in Brown Norway rats to study the
potential of VS eye drops (1 μg/ml in PBS) to treat CNV. The
experimental scheme to evaluate the therapeutic efficacy and
duration of VS treatment for CNV is depicted in Figure 2. The
vascularization in laser-induced CNV lesion in rats after VS
treatment was characterized using flat mount analysis after
perfusion  with  FITC-dextran  (Figure  3).  VS  treatment
significantly  reduced  the  CNV  area  (58,964±2,613  μm2)
compared with untreated CNV (96,764±4,563 μm2; p<0.01)
and thus was effective in suppressing CNV onset.
VS treatment diminished the area of CNV lesions by FAG
analysis: The therapeutic efficacy of VS eye drops (1 μg/ml
in PBS) over time was evaluated by using FAG to analyze
laser-induced CNV after VS treatment (Figure 4). VS-treated
eyes  had  less  fluorescent  dye  uptake  and  extent  of  CNV
(Figure 4A). In addition, CNV lesions areas in VS-treated rats
were significantly decreased on day 21 (3.5±1.11 mm2 versus
7.01±1.07 mm2 and 6.87±2.03 mm2 for untreated and PBS-
treated eyes, respectively; p<0.01), day 28 (5.27±1.06 mm2
Figure  3.  Flat  mount  analysis  of
choroidal vascularity in rat eyes after
topical VS application as determined by
FITC-dextran  injection.  A:  FITC-
dextran  positive  blood  vessels  are
presented  in  choroids  of  untreated  or
VS-treated animals. Arrows indicate the
laser-induced lesions. B: FITC-dextran
labeling CNV in untreated or VS-treated
eyes  are  quantified.  Data  are
summarized  as  mean±SEM  (n=8).
Double asterisk (**) represents p<0.01.
The scale bar equals 200 μm.
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1901versus 10.34±1.3 mm2, and 8.99±2.03 mm2 for untreated and
PBS-treated  eyes,  respectively;  p<0.05),  day  35
(6.11±1.33 mm2 versus 11.03±0.72 mm2 and 9.75±1.62 mm2
for untreated and PBS-treated eyes, respectively; p<0.05), and
day  42  (3.5±1.11  mm2  versus  7.01±1.07  mm2  and
6.87±2.03  mm2  for  untreated  and  PBS-treated  eyes,
respectively;  p<0.05;  Figure  4B).  Together,  these  results
indicate that topical VS application attenuated the severity of
experimental CNV despite declining efficacy over time.
Topical  VS  application  alleviated  CNV  and  reduced
subretinal neovascularization: To elucidate the therapeutic
mechanism of VS eye drops (1 μg/ml in PBS), we analyzed
rat  retinas  by  histologic  and  immunofluorescent  methods.
Hematoxylin and eosin staining showed that laser-induced
lesions  were  definitely  smaller  and  the  subretinal  tissues
relatively  intact  without  neovascularization  in  VS-treated
eyes compared to controls (Figure 5). In addition, examination
of blood vessel density revealed that the number of vWF-
positive blood vessels was significantly decreased in VS-
treated eye drops (1 μg/ml in PBS) compared to controls
(8±2.28  versus  3.78±1.16  per  high  power  field;  p<0.05;
Figure  6).  Therefore,  topical  VS  application  ameliorated
laser-induced  lesions  and  neovascularization,  thereby
disrupting CNV development.
Topically applied VS was detected in subretinal tissues: To
delineate whether topical VS reached choroids to exert its anti-
Figure  4.  Effect  of  topical  VS
application on CNV lesions in rats by
FAG. A: Representative photographs of
fundus  microscopy  (top  panels)  and
FAG (bottom panels) indicate the anti-
angiogenic  effect  of  topical  VS
application. Top: the laser spots in rat
eyes of different group are shown under
fundus  microscope.  Bottom:  FAG
analysis of CNV lesion in rat eyes by
group are shown on day 28. B: Effect of
topical VS application on the area of
CNV lesions in rats are evaluated by
FAG.  Areas  of  CNV  lesions  were
determined  by  FAG  examination  on
days  21,  28,  35,  and  42  after  laser
photocoagulation. Data are summarized
as  mean±SEM  (n=8)  and  are
representative  of  three  experiments.
Asterisk  (*)  represents  p<0.05,  and
double asterisk (**) represents p<0.01.
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1902angiogenic effect, we dissected ocular tissues from VS-treated
eyes.  Western  blot  analysis  revealed  exogenous  VS  in
retinochoroid  tissues  even  though  most  VS  protein
accumulated in the cornea (Figure 7). Thus, topically applied
VS could reach the choroids.
DISCUSSION
This  study  demonstrated  that  topical  VS  application
suppresses CNV. VS has the following advantages. First, VS
protein is highly soluble and stable in solution, making it
suitable for eye drop formulation and storage. Second, the
potency of VS is greater than that of endostatin or angiostatin
[13,14]. Third, the cytotoxicity of VS is highly specific; VS
selectively inhibited the proliferation of endothelial cells only,
and no other types of cells including retina or iris pigment
epithelial cells [16,17]. Finally, topical VS application does
not induce inflammation or other adverse effects in animals.
Huegel  et  al.  [23]  indicated  that  VS  may  possess  anti-
inflammatory  capabilities,  which  may  contribute  to  CNV
suppression. Our pilot study using electroretinography also
suggest  that  topical  VS  application  does  not  alter  retinal
functions in normal rats (data not shown).
Compared to intraocular injection, topical application is
a  noninvasive  route  for  drug  delivery  to  the  retina  with
minimal adverse effects. Furthermore, eye drops are used
routinely  for  long-term  treatment  of  glaucoma  in  clinical
practice. Some drugs have been shown to successfully reach
Figure 5. Histological analysis of CNV lesions in rat eyes after topical VS application. After final FAG analysis on day 42, rat eyes were
dissected and analyzed by hematoxylin and eosin analysis. VS application resulted in much smaller neovascularization. Arrows indicate the
laser-induced CNV lesions. Abbreviations: ganglion cell layer (GL); inner nuclear layer (INL); outer nuclear layer (ONL); choroid (CH).
Magnification is 100×.
Figure 6. Immunofluorescence analysis
of choroidal vascularity in rat eyes after
topical VS application. The choroidal
vascularity in PBS-treated or VS-treated
eyes  was  examined  by
immunofluorescence  analysis  using
anti-vWF. A: Profile of vWF-positive
vessels in choroids (C) and retina (R) of
PBS-treated  or  VS-treated  eyes  are
shown. Arrows indicate CNV by little
circles in low power filed (arrowheads)
and  big  circles  in  high  power  field
(larger arrows). B: PBS-treated vWF-
positive blood vessels in choroids are
nearly twice those of VS-treated eyes.
Data  are  summarized  as  mean±SEM
(n=8).  Asterisk  (*)  indicates  p<0.05.
The scale bar equals 200 μm.
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1903the vitreous cavity to treat retinochoroidal diseases [24-26].
Our eye distribution study by western blot analysis suggests
that  topically  applied  VS  can  be  transported  to  the
retinochoroid. One probable mechanism is that VS directly
penetrates the cornea into the retina. However, the corneal
epithelium represents the rate-limiting membrane for water-
soluble  substances  like  VS.  Alternatively,  VS  can  be
transported by a noncorneal route, such as via conjunctiva and
sclera. Evidence indicates that the sclera is permeable, even
to macromolecules, so that transscleral delivery can enable
drug transfer to the posterior segment [27]. Noncorneal routes
avoid the lens barrier and the counterflow of aqueous humor
[28]. Besides the corneal and noncorneal routes, we could not
rule out the possibility that VS is delivered to the posterior
ocular segment after systemic reabsorption. In this approach,
access to the choroids is feasible owing to the extensive blood
flow and highly permeable vessels in the retinochoroid. Future
studies are warranted to elucidate the transport mechanism of
topical VS therapy.
Because  it  takes  years  or  even  decades  for  CNV  to
develop in humans, it is debatable whether a protein or its gene
vector should be employed to achieve long-term prevention
or suppression of CNV. We have demonstrated the feasibility
of intramuscular, polymer-based VS gene therapy for CNV
suppression [17]. Though effective and devoid of compliance
problems,  systemic  VS  expression  may  alter  physiologic
processes,  such  as  wound  healing,  or  by  aggravating  the
cardiovascular  diseases.  Due  to  the  use  of  a  constitutive
promoter, another drawback of gene therapy is the inability to
stop the production of gene products when side effects occur.
In contrast, despite the short half-life of protein drugs in vivo,
topical VS administration has the following advantages: 1)
safety via local route; 2) feasibility to extend or terminate the
therapy; and 3) flexibility to modify the therapeutic dose. In
the present study, the efficacy of VS eye drops (1 μg/ml in
Figure 7. Immunoblot analysis of the distribution of topically applied
VS in rat eyes. Western blot analysis reveals that after 14 days of
topical VS application, there is greater 6xHis activity and less β-actin
in rat cornea (C) and retinochoroid (RC) compared to PBS-treated
rat C and RC.
PBS) indeed diminished as the experiments went on, probably
due  to  insufficiency  of  the  therapeutic  protein.  Future
experiments should be conducted to investigate whether dose
escalation or prolonged treatment could further improve the
therapeutic efficacy of VS for CNV.
To our knowledge, this study demonstrates for the first
time the potential for topical application of anti-angiogenic
protein for CNV. Since none of the experimental animals
showed overt adverse effects, VS eye drops (1 μg/ml in PBS)
may constitute a novel alternative for CNV. In addition, VS
suppresses multiple angiogenic pathways in endothelial cells
and may serve as an adjuvant therapy with VEGF-targeting
agents such as bevacizumab or ranibizumab for long-term
CNV  management.  Future  studies  on  optimal  dosage,
therapeutic mechanisms, and pharmacological kinetics of VS
are warranted for its ophthalmic application.
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